Sentences with phrase «outcome of therapy for»

Outcome of therapy for sexually abused children: A repeated measures study.

Relational factors in music therapy can contribute to a positive outcome of therapy for children with autism.

Not exact matches

From a value perspective, if the young adults with leukemia who respond to therapy end up with more years of life — an outcome that is quite likely — then Kymriah will be cost - effective for society as well.

Another recently approved one - time therapy, Novartis» Kymriah for a form of leukemia, also has an outcomes - based pledge: If the treatment isn't working after a month, Novartis doesn't get paid.

Creative / Play Therapy offers a space to freely express their feelings of sadness, anger, etc without a need for explanation, explore different outcomes and feel in charge of their created worlds.

Pediatric Therapy Network (PTN) was founded in 1996 by a handful of therapists, parents and volunteers who envisioned an organization that would provide the community with high quality therapy, research and education as it relates to fostering the best possible outcomes for children with specialTherapy Network (PTN) was founded in 1996 by a handful of therapists, parents and volunteers who envisioned an organization that would provide the community with high quality therapy, research and education as it relates to fostering the best possible outcomes for children with specialtherapy, research and education as it relates to fostering the best possible outcomes for children with special needs.

Additionally, by sticking to a routine of frequent and regular follow - up visits for the purpose of an outcome study, you can be confident that any possible problem your premature baby may encounter later on in life will be spotted immediately, and proper therapy can begin right away.

We searched PubMed, Embase, and Cochrane databases for randomised controlled trials of maintenance tocolysis therapy with nifedipine in preterm labour.We selected trials including pregnant women between 24 and 36 (6/7) weeks of gestation (gestational age, GA) with imminent preterm labour who had not delivered after 48hours of initial tocolysis, and compared maintenance nifedipine tocolysis with placebo / no treatment.The primary outcome was perinatal mortality.

The safety of the nicotine patch therapy during pregnancy was assessed by monitoring for these adverse pregnancy events and birth outcomes.

«Our research indicates that insertion of cervical pessary at around 22 weeks in both randomly selected women pregnant with twins and in patients with a short cervix of less than 25 millimeters does not reduce the rate of spontaneous early preterm birth, perinatal death, adverse neonatal outcome, or need for neonatal therapy.»

Researchers at the Veterans Health Administration conducted a systematic review of 67 published studies to determine the effectiveness of strategies to reduce or discontinue long - term opioid therapy prescribed for chronic pain and the effect of dose reduction or discontinuation on important patient outcomes.

Their findings could potentially enhance diagnosis of the disease and prediction of therapy outcomes for improved treatment successes.

In a related Editor's Note, Deborah Grady, M.D., M.P.H., a deputy editor of JAMA Internal Medicine, writes: «It is possible that treatment beyond one year would result in better outcomes, but these data provide no support for use of higher - dose cholecalciferol replacement therapy or indeed any dose of cholecalciferol compared with placebo.»

Researchers from Massachusetts Eye and Ear / Harvard Medical School have found that patients who were prescribed corticosteroids as part of treatment for Lyme disease - associated facial paralysis had worse long - term outcomes of regaining facial function than those who were prescribed antibiotic therapy alone.

Dr. Oktay noted that «the outcome for patients with metastatic breast cancer hasn't improved in the past 30 years despite the development of targeted therapies.

Intravenous thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) can improve outcomes for patients with ischemic stroke treated within 4 1/2 hours of the onset of symptoms.

The study, entitled COMET (Comparison of Operative to Medical Endocrine Therapy) for low - risk ductal carcinoma in situ, received funding through a $ 13.4 million, five - year award from the Patient - Centered Outcomes Research Institute (PCORI), an independent, nonprofit organization authorized by Congress in 2010 to support research that enlightens health care decisions.

Patients with BRAF mutations had similar outcomes for each of the therapies.

«We also are looking at comprehensive packages for getting patients involved in preventing other types of complications by asking them to report any symptoms of pneumonia or deep vein thrombosis and reminding them when and how often to exercise to improve physical therapy outcomes,» Ms. Lu said.

The results of the Endovascular Therapy Following Imaging Evaluation for the Ischemic Stroke (DEFUSE 3) trial, presented at the International Stroke Conference 2018 in Los Angeles and published on Jan. 24 in the New England Journal of Medicine, demonstrated that physically removing brain clots up to 16 hours after symptom onset in selected patients led to improved outcomes compared to standard medical tTherapy Following Imaging Evaluation for the Ischemic Stroke (DEFUSE 3) trial, presented at the International Stroke Conference 2018 in Los Angeles and published on Jan. 24 in the New England Journal of Medicine, demonstrated that physically removing brain clots up to 16 hours after symptom onset in selected patients led to improved outcomes compared to standard medical therapytherapy.

«The recent niacin clinical trials offer important new evidence that raising «good» cholesterol (HDL) levels on top of statin therapy does not have the positive outcome that had been hoped for,» said Neil Stone, M.D., the Robert Bonow MD Professor in Cardiology at Feinberg and a cardiologist at Northwestern Memorial Hospital.

For the outcome «morbidity,» there was an indication of a lesser benefit because more AIDS - defining events occurred under the elvitegravir fixed combination: about 23 out of 1000 versus 3 out of 1000 under the comparator therapy.

The Cost and Outcome of Behavioural Activation versus Cognitive Behavioural Therapy for Depression (COBRA) trial, one of the largest of its kind in the world, was designed to meet this need.

Tryfonidis et al. discuss perspectives and future directions for the management of locally advanced breast cancer in Nature Reviews Clinical Oncology, and they see a need for not only standardizing treatment for this disease, but also for developing new therapies that could substantially improve outcome.

Knowing which cells are best for the therapy should not only improve patient outcome, but also reduce the number of cells required, which would further reduce both the time of the preparation and invasiveness of the procedure.

Detailed evaluation of a prostate cancer tumor biopsy may predict treatment outcomes for image - guided radiation therapy (IGRT) or surgery for prostate cancer, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

These therapies could enhance the effects of novel cancer immunotherapies when used in combination, resulting in better health outcomes for cancer patients.

«Defining the biology of naturally occurring protective mutations is quite important, because they define desired outcomes for potentially new therapies,» explained the study's co-author Judy H. Cho, MD, Director of the Sanford Grossman Center for Integrative Studies in Crohn's disease, and the Charles F. Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai.

The next step will be to optimize the approach and to extend it to protein - protein interactions, protein - gene interactions, disease - protein interactions, disease - drug interactions all with a view to improving diagnostics and tailoring therapy for the individual patient based on the outcomes of their personal biological network analysis.

This new knowledge is also making precision medicine a reality by enabling the development of highly targeted therapies that offer the potential for improved treatment outcomes, especially for patients battling cancer.

Endovascular therapy within 24 hours is the standard of care for emergent large - vessel occlusion, but the chance of achieving a good outcome decreases by approximately 20 percent for each hour that passes before treatment.

Detailed evaluation of a prostate cancer tumor biopsy may predict treatment outcomes for image - guided radiation therapy (IGRT) or surgery for prostate cancer, according to research presented at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

These models are desperately needed for learning more about Group 4 medulloblastoma biology and evaluating rational, molecularly targeted therapies to improve patient outcomes,» said Paul Northcott, Ph.D., an assistant member of the St. Jude Department of Developmental Neurobiology.

They measured adherence to statin therapy and outcomes comprising of hospitalization for an acute coronary syndrome, stroke and mortality.

«The risk of cognitive impairment should be considered when deciding whether or not to receive androgen deprivation therapy for prostate cancer,» said Brian Gonzalez, Ph.D., a postdoctoral fellow in the Health Outcomes and Behavior Program at Moffitt.

Researchers reported promising preliminary outcomes for the first four children enrolled in a U.S. gene therapy trial for Wiskott - Aldrich syndrome (WAS), a life - threatening genetic blood and immune disorder, at the 57th annual meeting of the American Society of Hematology.

After analyzing the data, he and his collaborators in Berlin are convinced that the activity of Shp2 and its target genes can predict the outcome of breast cancer: The less active Shp2 is, the higher the chance for the affected women to stay relapse - free after having undergone a successful breast cancer therapy.

But there's reason for optimism - recent advances in screening and treatment, such as CAR T cell therapy, mean patient outcomes and quality of life are continuing to improve.

Renal outcomes with different fixed - dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial.

His research interests include redesigning health care delivery models to optimize outcomes for people with diabetes that has included examining the role of the Patient - Centered Medical Home, motivational interviewing, the Chronic Care Model, nurse case management, behavior change, innovative technologies and therapies, improved inpatient management, podiatric care and the use of registries.

The technology successfully tracked in real - time how the diversity of tumor cell populations were changing in response to particular therapies for all of the patients studied, and was highly predictive of treatment effectiveness and patient outcomes.

«Developing therapies for each subtype independent of the other may improve outcomes, as has been shown in breast cancer.»

Some form the basis for interventions — for example, a new treatment or a strategy for improving use of a proven therapy — that are tested to determine whether they can improve health outcomes.

Still, BioViva has pressed ahead with telomerase gene therapy, and factions within the research community are also aiming for the same outcome of human tests, though through more conventional channels.

Professor Ferner's research with national and international collaborators focuses on defining clinical phenotype in the neurofibromatoses, determining the natural history of optic pathway glioma and developing robust clinical and patient centred outcome measures for monitoring novel therapies.

LA JOLLA — Scientists at the Salk Institute for Biological Studies have identified a key genetic switch linked to the development, progression and outcome of cancer, a finding that may lead to new targets for cancer therapies.

A pathological complete response (pCR) after neoadjuvant chemotherapy (NCT) is a strong indicator of the benefit of therapy and presents an early surrogate for a favorable long - term outcome.

Anti-PD-1 antibody therapy enhances eradication of refractory Hodgkin lymphoma (HL), and when used in combination with other agents may help improve outcomes for leukemia patients, according to a report in the journal Leukemia Research.

[38] Although the results of the trials of cell therapy for PD were mixed, with only a minority of patients showing clear - cut and durable gains, researchers have subsequently gained substantial insight into the reasons underlying differential outcomes at different centers and amongst different protocols, and for the troubling dyskinesias that were suffered by some patients.

The work that garnered the honor, «An analysis of the risk and benefit of neoadjuvant chemotherapy among patients undergoing surgery for non-small cell lung cancer,» examined data from more than 134,000 patients in the National Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term survival.